Overview
- Researchers published a Nature Communications paper describing PROTEXI, a dendritic cell vaccine platform that pairs tumor antigens with short helper peptides from the SARS‑CoV‑2 Spike protein.
- The vaccine works by using pre‑existing antiviral CD4+ helper T‑cell memory to boost tumor‑specific CD8+ cytotoxic T cells and to create durable antitumor immune memory.
- In multiple mouse models of melanoma and breast cancer, PROTEXI slowed tumor growth, improved survival, and changed immune‑cold tumors so they were more readily recognized by the immune system.
- Effectiveness was also seen in humanized mouse experiments that used immune cells from COVID‑19–vaccinated donors, strengthening the case for testing the approach in people.
- Celloram and University Hospitals are preparing a first‑in‑human sarcoma trial to evaluate safety, feasibility, and immune activity, but clinical safety and benefit in patients remain unproven and will require further study and regulatory review.